Ocid-DSR

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ocid-DSR

Property Description
Active ingredient Omeprazole and Domperidone
Form Delayed-Release (DSR) Oral Capsule
Pharmacological class Proton Pump Inhibitor (PPI) & Prokinetic Drug
Origin Synthetic compound combination

Defining Ocid-DSR: Identity and Composition

Ocid-DSR is an orally administered Fixed-Dose Combination (FDC) medicine containing the synthetic active ingredients Omeprazole and Domperidone. This prescription formulation is classified as an Antireflux and Antiulcerant agent, designed to provide combined action against symptoms arising from acid-related disorders and motility dysfunction. The combination of the H^+K^+-ATPase inhibitor Omeprazole alongside the dopamine antagonist Domperidone is a strategy for managing gastrointestinal reflux symptoms.

The purposeful FDC design, featuring the acid-suppressing Omeprazole and the motility-enhancing Domperidone, is what primarily differentiates this product from single-agent treatments, offering a dual mechanism that addresses two underlying causes of discomfort simultaneously.

Pharmacological Class and Dual Action

The medicine belongs to two distinct pharmacological classes: Omeprazole is a Proton Pump Inhibitor (PPI), and Domperidone is a Prokinetic Drug. Omeprazole achieves potent and sustained acid suppression by inhibiting the final phase of acid secretion. Concurrently, Domperidone acts as a peristaltic stimulant, enhancing the speed and coordination of muscular contractions in the upper digestive tract. Domperidone promotes gastric emptying.

This combination is typically reserved for conditions where patients experience not only excessive acidity but also symptoms of slow stomach emptying, such as discomfort and fullness.

The DSR Formulation and General Purpose

The DSR designation indicates a specialized Delayed-Release Oral Capsule, a distinguishing feature of the formulation necessary for optimal component function. This design protects the acid-sensitive Omeprazole component, ensuring the active ingredient is released and absorbed only after passing into the small intestine. The general purpose of this specific delivery system and combination is to provide reliable and prolonged control for upper gastrointestinal issues by optimizing the bioavailability of the acid-suppressing ingredient while facilitating the coordinated clearance of stomach contents.

What side effects are possible with Ocid-DSR?

Possible side effects and safety information

The safety profile for this fixed-dose combination medicine is based on the documented adverse reactions and official safety constraints of its two active components, Omeprazole and Domperidone.


Frequency-Classified Adverse Reactions

Regulatory documents classify certain effects by frequency. Common reactions (occurring in 1/100 to 1/10 patients) primarily involve gastrointestinal disorders such as abdominal pain, nausea, diarrhea, vomiting, flatulence, and dry mouth, as well as headache. Uncommon reactions (1/1,000 to 1/100) may include insomnia, rash, vertigo, and an increased risk of bone fracture, specifically associated with the Omeprazole component.

Serious Adverse Reactions and Safety Constraints

The most critical safety constraint concerns the Domperidone component, which is associated with a risk of serious ventricular arrhythmias, including QTc prolongation and sudden cardiac death. Use is therefore contraindicated in patients with pre-existing cardiac conditions, significant electrolyte disturbances, or moderate to severe hepatic impairment.

Other serious adverse reactions documented in regulatory labeling include Acute Tubulointerstitial Nephritis (a severe kidney reaction) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), associated with the Omeprazole component.

Exposure-Related and Population-Specific Notes

Specific risks are tied to the duration of use. Daily, long-term exposure (typically longer than one year) to the Omeprazole component is linked to an increased risk of osteoporosis-related fractures (hip, wrist, or spine) and may lead to Vitamin B12 deficiency after extended periods (e.g., greater than three years). Safety labels also specify that the medicine is contraindicated in conditions where stimulating gastric motility could be harmful, such as gastrointestinal hemorrhage or mechanical obstruction.

The regulatory safety profile is thus structured around these frequency classifications and critical population- and duration-based restrictions.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Ocid-DSR

This section details the officially documented signs of overdose and the immediate emergency actions required, strictly based on government regulatory labeling for the combination of Omeprazole and Domperidone.

Feature Official Regulatory Statements
Documented Manifestations Symptoms may include drowsiness (somnolence), disorientation, confusion, agitation, and extrapyramidal reactions (involuntary muscle movements), alongside tachycardia (rapid heartbeat), headache, nausea, and vomiting.
Physiological Systems Affected Primarily the Central Nervous System (CNS) and the Cardiovascular System (cardiac electrical activity), in addition to the gastrointestinal system.
Dose-Related Risk The risk of QT interval prolongation (a serious cardiac electrical abnormality) is explicitly documented as dose-dependent with the Domperidone component.
Emergency-Response Action No specific antidote is known for this combination. Management is limited to symptomatic and supportive treatment.
Required Monitoring Management requires continuous Electrocardiogram (ECG) monitoring and hospital observation due to the cardiac risks associated with the Domperidone component.
Population-Specific Notes Infants and children may exhibit a higher frequency of CNS disturbances and extrapyramidal reactions following overdose.

When Immediate Medical Help is Required (Label-Derived Phrasing Only):

Patients must seek immediate medical attention or contact emergency services upon any suspicion of overdose or if severe signs such as convulsions, coma, or signs of cardiac arrhythmia are observed. The potential for life-threatening cardiac outcomes necessitates prompt professional care.


The regulatory documents define the overdose profile through the combined CNS and cardiac risks associated with the Domperidone component and the systemic effects of Omeprazole. Since no specific antidote is known, regulatory texts mandate immediate help-seeking and reliance on supportive treatment, including required continuous monitoring like ECG, to manage potential severe effects.

Therapeutic Uses of Ocid-DSR

Understanding Ocid-DSR: Main Uses and Benefits

Ocid-DSR is a combination medication designed to manage gastrointestinal conditions characterized by excessive acid production and motility issues. By combining two distinct active mechanisms, it addresses both the chemical and physical aspects of acid-related distress.

Primary Conditions Treated

This medication is primarily used to manage symptoms associated with the following conditions:

  • Gastroesophageal Reflux Disease (GERD): This is a chronic condition where stomach acid frequently flows back into the esophagus. The backward flow (acid reflux) can irritate the lining of the food pipe, leading to discomfort and potential tissue damage.
  • Peptic Ulcer Disease: Ocid-DSR is utilized in the management of ulcers that develop on the inner lining of the stomach and the upper portion of the small intestine (duodenum).
  • Dyspepsia: It helps alleviate symptoms of functional dyspepsia, which includes recurring indigestion or upper abdominal pain that does not have an obvious structural cause.

Therapeutic Benefits

The dual-action approach of Ocid-DSR provides several therapeutic advantages for those experiencing gastric distress:

Acid Suppression

One component of the medication works by inhibiting the proton pumps in the stomach lining. This significantly reduces the volume of hydrochloric acid produced, allowing the esophageal and gastric mucosa time to heal and preventing further irritation from acid exposure.

Improvement in Gastric Motility

The second component acts as a prokinetic agent. It enhances the movement of the muscles in the digestive tract, specifically by:

  • Increasing the tone of the lower esophageal sphincter, which helps prevent acid from escaping upward.
  • Accelerating gastric emptying, ensuring that food and acid move more quickly from the stomach into the intestines.

Symptom Relief

By addressing both acid levels and digestive transit, the medication effectively manages the common symptoms of reflux and indigestion, such as:

  • Heartburn: The burning sensation in the chest or throat caused by acid reflux.
  • Regurgitation: The feeling of acid or sour-tasting fluid backing up into the mouth.
  • Nausea and Vomiting: Reducing the sensation of fullness and the urge to vomit often associated with slowed digestion.
  • Epigastric Pain: Relieving the localized discomfort or aching in the upper abdomen.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ocid-DSR?

The population eligibility for Ocid-DSR, a combination medicine containing Omeprazole and Domperidone, is strictly governed by the regulatory safety profile of its components, particularly the restrictions on Domperidone use mandated by international health authorities.

Absolute Contraindications

Ocid-DSR is absolutely contraindicated (must not be used) in patients with specific comorbidities, primarily related to cardiac and hepatic function:

  • Known cardiac conduction prolongation (especially QTc interval) or underlying cardiac diseases such as Congestive Heart Failure.
  • Significant electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia).
  • Moderate or severe hepatic impairment (liver failure).
  • Gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Age and Physiological Restrictions

Population Official Regulatory Status
Children (Under 12 years or < 35 kg) Not Licensed / Not Recommended (Safety and efficacy not established).
Older Adults (Over 60 years) Use associated with a higher cardiac risk; requires careful consideration.
Pregnancy/Lactation Not Recommended (Domperidone is excreted into human milk, and cardiac effects in the infant cannot be excluded).

Patients with severe renal impairment require mandatory modification of the dosing frequency, as directed by official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details documented interaction information based on official regulatory sources for the combination product Ocid-DSR (Omeprazole/Domperidone). These interactions primarily involve changes in drug concentration or additive effects on the body's systems.

Interaction Scope

Category Description
Medicinal product categories with documented interactions Gastric pH-dependent drugs (e.g., certain antifungals, iron salts), CYP3A4 inhibitors/inducers, Drugs that prolong the QT interval, Antiarrhythmics, Protease Inhibitors.
Mechanistic basis of interactions Pharmacokinetic alteration (Absorption) due to reduced gastric acidity by Omeprazole; Pharmacokinetic alteration (Metabolism) via inhibition/induction of CYP3A4; Pharmacodynamic interaction (additive risk of QTc prolongation).

Official Interaction Statements

The Domperidone component necessitates restrictions on co-administration with strong CYP3A4 inhibitors and medicines known to prolong the QTc interval. This restriction is due to a substantial increase in Domperidone exposure, which elevates the risk of serious cardiac rhythm disturbances.

Omeprazole, by reducing intragastric pH, can significantly reduce the absorption and bioavailability of drugs whose uptake is dependent on an acidic environment (e.g., ketoconazole, itraconazole). Monitoring is also required when co-administering with methotrexate because Omeprazole can increase its plasma concentration. Patients taking warfarin should be monitored closely upon starting or stopping Ocid-DSR, as changes in coagulation time have been documented.

This profile defines specific constraints, compelling the avoidance of certain combinations and mandating monitoring for others, to manage the combined effects of reduced acidity and metabolic interference.

Mechanism of Action

Ocid-DSR is a fixed-dose combination product containing omeprazole and domperidone.

Omeprazole is a proton pump inhibitor (PPI), a class of molecules that irreversibly inhibits the H^+ / K^+-ATPase enzyme system (the gastric proton pump) located on the secretory surface of the gastric parietal cell. Omeprazole, a substituted benzimidazole, is a prodrug that becomes activated in the highly acidic canaliculi of the parietal cell. The activated sulfenamide moiety of omeprazole forms a covalent disulfide bond with cysteine residues on the extracellular domain of the proton pump. This irreversible covalent modification prevents the exchange of H^+ ions for K^+ ions, thereby blocking the final common pathway of gastric acid secretion.

Domperidone acts as a peripheral dopamine D2 receptor antagonist. Its molecular targets are primarily D2 receptors located in the gastrointestinal tract (enteric nervous system). By binding to and blocking these receptors, domperidone modulates cholinergic neurotransmission and gastrointestinal smooth muscle function. The downstream cascade involves an increase in lower esophageal sphincter pressure and enhanced gastric antral and duodenal motility, accelerating the transit of luminal contents.

Dosage and Administration Information

How to Use Ocid-DSR

The administration of the Omeprazole and Domperidone combination is defined by a specific route, timing, and regimen necessary for the product's Fixed-Dose Combination (FDC) and Delayed-Release (DSR) design.


Official Administration Guidelines

Ocid-DSR is an orally administered medication and the route of delivery is swallowing the capsule.

Dosing and Frequency: The standard regimen is typically one capsule once daily. The capsule contains the established components for acid suppression and prokinetic action (e.g., Omeprazole 20 mg and Domperidone 10 mg equivalent), with the daily dosage generally not exceeding established safety constraints for the Domperidone component.

Timing and Preparation: To ensure the maximum therapeutic effect, the capsule must be taken before a meal, typically 30 to 60 minutes before breakfast. The Delayed-Release Capsule must be swallowed whole with water. It is a critical procedural constraint that the capsule must not be crushed, chewed, or opened as this action would damage the enteric coating and compromise the Omeprazole component's absorption.


Procedural and Population Constraints

Course Duration: Therapy is generally intended for a short-term, time-limited duration. Continuous long-term use is not typically part of the standard label.

Dose Adjustment: Specific dose modifications are required for patients with pre-existing conditions. For the Domperidone component, use is generally restricted or contraindicated in moderate-to-severe hepatic impairment, and the dosing frequency requires reduction in severe renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ocid-DSR

This section describes the research that has explored the combination of Omeprazole and Domperidone (Ocid-DSR), focusing on the types of studies conducted and areas where data are still limited.

Evidence for Use in Gastroesophageal Reflux Disease (GERD)

Research primarily explored this combination for GERD using Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies tracked outcomes related to physical discomfort, like changes in heartburn and the healing status of the esophagus using specialized medical techniques. Comparative trials examined patterns in global symptom scores and patient-reported quality of life (QoL). The follow-up durations were limited, and scientific literature noted that findings were mixed regarding QoL scores compared to monotherapy.

Evidence for Use in Functional Dyspepsia and Chronic Gastritis

The evidence for conditions such as Functional Dyspepsia (FD) and Chronic Superficial Gastritis is largely derived from Prospective Observational Studies and smaller, open-label cohorts. Research monitored outcomes reflecting daily functioning, such as upper abdominal pain and fullness, over short intervals. Comparative evidence is lacking, and the certainty remains low in this area due to modest sample sizes.

Research on Laryngopharyngeal Reflux (LPR) Symptoms

The combination was studied for LPR using prospective, comparative randomized studies. Researchers assessed changes in symptom severity using specialized scales. Research indicates that the total LPR symptom scores were not consistently distinguishable between the combination and Omeprazole monotherapy.

Long-Term Studies and Durability of Response

Available research provides context concerning the sustained nature of observed changes. Follow-up durations were limited, meaning that data for long-term outcomes are still emerging. The long-term characterization and durability of response are not fully established.

Research in Special Populations

The research has predominantly been conducted on the general adult population, including those with co-morbidities like Type 2 Diabetes Mellitus. However, data for certain groups, such as children, adolescents, or frail older adults, remain insufficient.

What is Still Uncertain About Ocid-DSR Research

A primary limitation is the lack of comparative evidence for certain indications. The subgroup findings are uncertain due to limited patient numbers. Overall, more large-scale, methodologically rigorous, long-term studies are needed to fully characterize the sustained role of this combination.

Frequently Asked Questions (FAQ)

Common questions about Ocid-DSR (FAQ)


Q: How quickly should I expect Ocid-DSR to start working?

The medicine has two components with different timelines. The Domperidone component, which helps with stomach movement, often begins working within 30 to 60 minutes after taking the capsule on an empty stomach. The acid-suppressing component, Omeprazole, is in a delayed-release form, meaning the full effect on reducing stomach acid may take a few days to fully develop.


Q: What happens if a dose of Ocid-DSR is forgotten?

If a scheduled dose is missed, regulatory guidance generally advises omitting that dose completely. The guidance is to resume the usual dosing schedule at the next scheduled time. Official instructions state that you should not take a double dose to make up for a forgotten one.


Q: Can Ocid-DSR be crushed or chewed?

No. Official administration instructions emphasize that the Delayed-Release capsule is to be swallowed whole with water. It should not be crushed, chewed, or opened, as this can damage the protective coating, which is essential for ensuring the Omeprazole component is absorbed correctly. Damaging the coating may compromise the drug's effectiveness.


Q: Can taking Ocid-DSR affect my sleep?

Yes, official product information lists effects on sleep. Insomnia (difficulty sleeping) is noted as an uncommon adverse reaction associated with the Omeprazole component.


Q: Are headaches a commonly reported side effect of Ocid-DSR?

Yes, according to official prescribing documents, headache is listed as a common side effect. This means it has been frequently reported in a significant number of patients.


Q: Are there any food or drinks that should be avoided when taking Ocid-DSR?

Official guidance stresses that the capsule should be taken before a meal. Some product safety information may also advise against consumption of grapefruit juice or alcohol. This is because alcohol can potentially worsen acidity symptoms, and grapefruit juice may affect how the drug is processed in the body.


Q: Can Ocid-DSR change the way other medications are absorbed?

Yes. The Omeprazole component works by reducing the acid level in the stomach. Official product information states that this change in stomach acid can reduce the absorption and effectiveness of other medications whose uptake requires an acidic environment. Examples include certain antifungal medicines and iron salts.


Q: Is Ocid-DSR known to interact with antibiotics?

Interactions may exist with certain antibiotics. Some antibiotics can interfere with the way the liver breaks down the drug components (via the CYP3A4 enzyme), which may lead to altered drug concentrations. Any co-administration should be reviewed by a health professional.


Q: Does Ocid-DSR interact with anxiety or depression medicines?

Yes, interactions with some medicines used for anxiety or depression are possible. This is because these drugs may share the same metabolic pathways (liver enzymes like CYP2C19/CYP3A4) that process Omeprazole. This overlap could alter the concentration of either medicine, and monitoring may be necessary.


Q: Does Ocid-DSR affect kidney function?

Official documents note two aspects regarding kidney function. Firstly, uncommon adverse reactions associated with the Omeprazole component include a severe kidney reaction called Acute Tubulointerstitial Nephritis. Secondly, the dose must be adjusted or restricted for patients with severe pre-existing kidney impairment due to the Domperidone component.


Q: Does Ocid-DSR interact with any herbal supplements?

Yes, some herbal products may interact with this medicine. For instance, St. John’s Wort is noted in some official product monographs as potentially affecting the concentration of Omeprazole in the body. Patients are typically advised to disclose all herbal product use to their health professional.


Q: Can Ocid-DSR cause stomach pain or cramping?

Yes, official safety information lists effects on the gastrointestinal tract. Abdominal pain, which may be felt as a cramping sensation, is included as a common side effect associated with this medication.


Q: What are the most frequent side effects listed for Ocid-DSR?

Official prescribing documents classify certain effects by their frequency. The most frequent (or common) side effects reported include headache, abdominal pain, nausea, diarrhea, vomiting, flatulence (gas), and dry mouth.


Q: Is there a link between Ocid-DSR and vitamin B12 levels?

Yes. The Omeprazole component, like other acid-blocking medicines, may reduce the absorption of Vitamin B-12 (cyanocobalamin). This effect is generally associated with daily long-term use, typically when the medicine is taken for longer than one year.


Q: Has Ocid-DSR been studied for use during pregnancy?

Official information states that the medicine is not recommended during pregnancy or while breastfeeding. This recommendation is based on findings from animal studies that indicated potential risk, and the fact that the Domperidone component can be excreted in human milk.


Q: Can Ocid-DSR be used by children?

No, Ocid-DSR is not licensed or recommended for use in children under 12 years of age or those weighing less than 35 kg. Official safety and effectiveness data for this age group have not been established.


Q: Does alcohol consumption affect how Ocid-DSR works?

Official safety information may advise against or warn about consuming alcohol while taking this medicine. While a direct interaction with the drug's mechanism is not always cited, alcohol can worsen the underlying acidity symptoms the medicine is intended to manage. It can also enhance certain central nervous system side effects, such as dizziness.


Q: Why does my doctor prescribe Ocid-DSR instead of another acid-reducing drug?

Regulatory indications suggest that the fixed-dose combination (FDC) of Omeprazole and Domperidone is typically reserved for conditions that have not responded adequately to Omeprazole alone. This implies the patient has symptoms that require both potent acid suppression and the prokinetic (motility-enhancing) action of Domperidone.


Q: What are the main findings from clinical trials on Ocid-DSR?

Clinical research primarily supports the combination's use in Gastroesophageal Reflux Disease (GERD) for improving overall symptom scores and healing in the esophagus. However, research documents note that findings are often mixed regarding whether the combination is superior to Omeprazole used alone. Furthermore, long-term safety and outcome data remain limited.


Q: Do all drug regulatory agencies approve Ocid-DSR for the same conditions?

No, the approved uses can vary between different international regulatory agencies. The Domperidone component, in particular, has seen its approved indications restricted by some authorities, such as the European Medicines Agency (EMA), primarily due to concerns over cardiovascular risk. This can lead to variations in the specific conditions the combination product is approved to treat.


Q: Is Ocid-DSR used to stop feeling nauseous?

Yes, the Domperidone component of Ocid-DSR is an antiemetic drug, meaning it is indicated for the relief of the symptoms of nausea and vomiting. Its action helps by enhancing movement in the upper digestive tract.


Q: Can Ocid-DSR make you feel dizzy?

Yes, official product information lists dizziness as a possible side effect. Dizziness is noted as an uncommon adverse reaction associated with the Omeprazole component and is a known effect of the Domperidone component as well.


Q: Does Ocid-DSR cause gas or bloating?

Yes, official safety information lists effects on the gastrointestinal tract. Flatulence (gas) is a common side effect, and general gastrointestinal disorders are common adverse reactions noted in regulatory documents.


Q: Are there different strengths available for Ocid-DSR?

Official prescribing information typically details all available dosage forms and strengths. While a standard combination strength is common, it is possible for multiple omeprazole/domperidone strengths to be approved depending on the specific region. You should check the label for your specific product.


Q: Is a metallic taste in the mouth possible with Ocid-DSR?

Yes, official documents indicate that taste disturbance is listed as a rare side effect associated with the Omeprazole component. This may be perceived by some users as a metallic taste.


Q: What is the risk of allergic reaction to Ocid-DSR?

The risk of allergic reaction is present, as with all medications. Official regulatory documents list hypersensitivity reactions as rare adverse reactions, including severe forms such as anaphylactic shock and angioedema. Any signs of a severe reaction require immediate medical attention.


Q: What should I do if I experience an unusual side effect while on Ocid-DSR?

Official patient counseling information describes that a health professional is typically contacted immediately if serious or unusual symptoms are experienced. Serious side effects, such as an irregular heartbeat, severe rash, or signs of an allergic reaction, require immediate medical attention.


Q: Can Ocid-DSR affect the results of certain medical tests?

Yes. The Omeprazole component is known to potentially interfere with specific diagnostic investigations. This includes certain tests for neuroendocrine tumors and may also affect the results of some urine drug screens.


Q: Is Ocid-DSR generally considered a safe option for managing acidity?

Official regulatory documents define the safety of this medication through its use restrictions. The use of Ocid-DSR is strictly contraindicated (must not be used) in patients with underlying cardiac diseases, moderate or severe liver impairment, or significant electrolyte disturbances. These constraints are in place due to the cardiac risks associated with the Domperidone component.


Q: Is it okay to take Ocid-DSR with common pain relievers?

The Omeprazole component may interact with some common pain relievers, particularly those metabolized by the CYP2C19 enzyme. While Ocid-DSR is often prescribed to help heal ulcers caused by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), co-administration with any pain reliever is often subject to review by a health professional.

How should Ocid-DSR be stored and disposed of?

Ocid-DSR (Omeprazole and Domperidone) capsules must be stored correctly to maintain their stability and effectiveness.

Storage

  • Store the medicine in its original container or packaging with the lid tightly closed.
  • Keep it in a cool, dry place, protected from excessive moisture, heat, and direct light.
  • The ideal storage temperature is generally below 30^circC (86°F), or as instructed on the packaging.
  • Ensure the medication is kept securely out of the sight and reach of children and pets.

Disposal

  • Do not use the medicine if it is expired.
  • Do not flush unused or expired capsules down the toilet or pour them into a drain unless specifically instructed by a healthcare professional or drug take-back guidance.
  • The best method for disposal is often through a local drug take-back program or community disposal event.
  • If a take-back program is unavailable, mix the medicine with an unappealing substance, like dirt or used coffee grounds, seal it in a plastic bag, and discard it in your household trash. Scratch out all personal information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ocid-DSR found in:

A-Z Index: